Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01467661
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date October 27, 2010
Completion date May 1, 2015

See also
  Status Clinical Trial Phase
Completed NCT01198717 - Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Completed NCT01214915 - Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Phase 3
Active, not recruiting NCT02577926 - The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Phase 2
Completed NCT03625895 - Agrylin Drug Use-Result Survey
Completed NCT01816256 - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms N/A
Completed NCT01352585 - Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Completed NCT04243122 - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Phase 2